Arthrex Launches Patient Education Website for ACL Injuries

ACLTear.com to educate, connect patients suffering from common knee injuries with surgeons trained in innovative procedures

Arthrex, a global leader in minimally invasive orthopedic technology, launched a new patient-focused website, ACLTear.com, which illustrates the science of anterior cruciate ligament (ACL) injuries, highlights the benefits of knee preservation technology and provides tools to patients to connect with surgeons performing advanced, minimally invasive ACL procedures.

“As the innovation leader in arthroscopic surgery, Arthrex is defining the future for how ACL injuries are treated,” said Arthrex President and Founder Reinhold Schmieding. “ACLTear.com is a tremendous educational resource for patients who want comprehensive information based on extensive orthopedic research and real patient experiences.”

Arthrex recently released two solutions for minimally invasive ACL preservation: the ACL Repair TightRope® implant and the SwiveLock® ACL Repair Kit, the first of its kind in the orthopedic industry to gain FDA clearance. Unlike a reconstruction or complete replacement of the ACL, the new technology enabling the preservation of a patient’s own ACL may allow for an easier recovery1 with a more normal-feeling knee2 and a possible faster return to activity.3

“Arthrex is dedicated to helping patients gain a better understanding of their injuries and the techniques available to improve their outcomes,” said Senior Director of Product Management, Knee and Hip Arthroscopy Jake Jolly. “ACLTear.com is an educational hub for anyone suffering from an ACL injury to explore their treatment options and connect with expert surgeons nearby.”

Arthrex has been involved in developing ACL repair and reconstruction techniques since 1983, with the goal of creating less invasive procedures to assist patients in returning to activity more quickly. In developing these techniques, the company has thoroughly studied the procedures and associated clinical outcomes in high-impact peer-reviewed literature.1,4-6

ACL tears and sprains are among the most common sports injuries in the U.S., with an estimate of between 100,000 to 200,000 occurrences every year.7 Younger and sports-active patients are predominately affected, typically by twisting or hyperextension.

ACLTear.com offers an interactive Find a Doctor tool to help patients quickly and easily connect with surgeons in their area.

SourceArthrex,

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version